Ironwood Pharmaceuticals (NASDAQ: IRWD) Form 3 names officer Jeffrey Silber

Rhea-AI Filing Summary

IRONWOOD PHARMACEUTICALS INC filed an initial insider ownership report identifying Jeffrey Silber, its SVP, CMO and Head-Res&Drug, as the reporting person. The filing notes Exhibit 24, a Power of Attorney, and shows no insider share transactions in this record.

Key Terms

Power of Attorney, Exhibit 24, SVP, CMO, Head-Res&Drug

3 terms

Power of Attorney regulatory

"Remarks include: Exhibit 24: Power of Attorney"

A power of attorney is a legal document that allows one person to make decisions and act on behalf of another person, often in financial or legal matters. It’s like giving someone a trusted helper or agent the authority to handle important tasks if you are unable to do so yourself. This matters to investors because it can impact how their assets are managed or transferred if they become unable to oversee their affairs.

Exhibit 24 regulatory

"Remarks include: Exhibit 24: Power of Attorney"

SVP, CMO, Head-Res&Drug other

"Officer title listed as SVP, CMO, Head-Res&Drug"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding Insider Trading Forms →

Available on EDGAR 07/22/2026 - 04:05 PM Accepted by SEC EDGAR 07/22/2026 - 04:05 PM Learn about SEC filing dates

FAQ

What does the IRWD Form 3 filing for Jeffrey Silber disclose?

It identifies Jeffrey Silber as SVP, CMO and Head-Res&Drug and as a reporting person for IRWD. The filing also references Exhibit 24, a Power of Attorney, and reports no insider share transactions in this data.

Who is the reporting insider named in Ironwood Pharmaceuticals (IRWD) Form 3?

The reporting insider is Jeffrey Silber, serving as SVP, CMO and Head-Res&Drug at Ironwood Pharmaceuticals. His position makes him an officer subject to SEC insider reporting requirements for ownership and certain equity-related activities.

Does the IRWD Form 3 for Jeffrey Silber report any stock transactions?

No. The structured Form 3 data for Jeffrey Silber shows zero reported purchases, sales, exercises, gifts, or other equity transactions, indicating only an initial insider ownership reporting setup in this record.

What is the role of Exhibit 24 in the IRWD Form 3 for Jeffrey Silber?

Exhibit 24 is a Power of Attorney authorizing designated individuals to sign and submit SEC ownership reports for Jeffrey Silber. This allows his insider filings to be executed and filed on his behalf in an official manner.

What officer title does Jeffrey Silber hold at Ironwood Pharmaceuticals (IRWD)?

Jeffrey Silber holds the title "SVP, CMO, Head-Res&Drug" at Ironwood Pharmaceuticals. This indicates he is a senior vice president and chief medical officer overseeing research and drug activities at the company.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Silber Jeffrey

(Last) (First) (Middle)

C/O IRONWOOD PHARMACEUTICALS, INC.

100 SUMMER STREET, SUITE 2300

(Street)

BOSTON MASSACHUSETTS 02110

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
07/20/2026

3. Issuer Name and Ticker or Trading Symbol
IRONWOOD PHARMACEUTICALS INC [ IRWD ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, CMO, Head-Res&Drug

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit 24: Power of Attorney

No securities are beneficially owned.

	/s/ Amir Vitale, Attorney-in-Fact	07/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)